Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

Current Opinion in Oncology

Volumn 12, Issue 6, 2000, Pages 594-597

  O'Dwyer, Michael E ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; LIGAND BINDING; MALIGNANT TRANSFORMATION; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0034509139     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200011000-00013     Document Type: Review

References (21)

1. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
2. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges
3. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
4. A minute chromosome in human chronic granulocytic leukemia
5. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
6. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
7. The viral and cellular forms of the Abelson (abl) oncogene
8. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
9. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
10. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
11. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
12. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
13. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL leukemic cells and induces apoptosis
14. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: Activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
15. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
16. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
17. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
18. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
19. Efficacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells
20. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
21. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia